Hospital de Transplante Doutor Euryclides de Jesus Zerbini Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03879486
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Hospital de Transplante Doutor Euryclides de Jesus Zerbini

Active Ingredients

Drugs in Phase 2 Trials (1)

nitazoxanide (Alinia) (1 trial)

Drugs in Other Trials (2)

formalin (1 trial)

povidone-iodine (betadine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3